The investment from AXA IM Alts will support and expand access to the Leva Pelvic Health System, a digital therapeutic that guides users through pelvic floor muscle training for the at-home treatment of incontinence. The system has received FDA clearance, according to a Feb. 16 Axena news release.
“We’re intently focused on combining novel technology, rigorous, peer-reviewed data and excellence in patient support to shine a light on what remains a vastly underserved area of women’s health,” Axena Health Chief Medical Officer Samantha Pulliam, MD, said. “The Leva Pelvic Health System can help women ease the burden of incontinence at home, on their own schedule, and allow them to re-engage with the activities that make them feel whole. We’re excited to have the opportunity to deliver these benefits to more women here in the U.S. and soon throughout the world.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.